{
  "abstract": "Cholangiocarcinoma (CCA) represents a heterogeneous and highly aggressive group of malignancies arising from the epithelial cells of the biliary tract. Although relatively uncommon, CCA has gained clinical relevance due to its steadily increasing global incidence and mortality. CCA now accounts for approximately 3% of gastrointestinal malignancies, ranking as the second most common hepatobiliary tumour. One of the most significant challenges in managing CCA lies in its typically asymptomatic presentation in early stages, leading to late diagnoses, when surgical resection, the only potentially curative option, is no longer viable.1 The prognosis for patients with CCA remains dismal, with 5-year survival rates below 20%.1 This poor outcome is compounded by the tumour’s genomic, epigenetic and molecular heterogeneity, which limits the efficacy of existing systemic therapies. In particular, the suboptimal performance of current chemotherapy and immunotherapy regimens highlights the urgent need for more effective treatment strategies. This therapeutic gap is largely attributable to an incomplete understanding of the molecular mechanisms driving CCA pathogenesis, underscoring the importance of elucidating its underlying biology to inform rational drug development.",
  "authors": [
    {
      "affiliations": [
        "Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain",
        "Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain"
      ],
      "name": "Elisa Lozano"
    },
    {
      "affiliations": [
        "Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain",
        "HepatoBiliary Tumours Lab, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain"
      ],
      "name": "Javier Vaquero"
    }
  ],
  "title": "Aurora kinase B at the nexus of cholesterol metabolism and therapy response in cholangiocarcinoma",
  "uid": "b9706cac-4111-57eb-a1a6-5385607b441e"
}